A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: Protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Wiegand, Kimberly C ^a   Hennessy, Bryan T ^e   Leung, Samuel ^d   Wang, Yemin ^a   Ju, Zhenlin ^b   McGahren, Mollianne ^b   Kalloger, Steve E ^a   Finlayson, Sarah ^a   Stemke Hale, Katherine ^b   Lu, Yiling ^b   Zhang, Fan ^b   Anglesio, Michael S ^a   Gilks, Blake ^a,d   Mills, Gordon B ^b   Huntsman, David G ^a,c,d   Carey, Mark S ^a,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF TEXAS   (United States)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d VANCOUVER GENERAL HOSPITAL   (Canada)

^e BEAUMONT HOSPITAL   (Ireland)

Author keywords

AKT; ARID1A BAF250a; Ovarian cancer; Phosphorylation; PIK3CA mutation; Proteomics

Indexed keywords

BAF250A; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; TUMOR PROTEIN; UNCLASSIFIED DRUG; ARID1A PROTEIN, HUMAN; NUCLEAR PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; PROTEOME; TRANSCRIPTION FACTOR;

ARID1A GENE; ARTICLE; CANCER STAGING; CLEAR CELL CARCINOMA; CONTROLLED STUDY; ENDOMETRIOID CARCINOMA; ENDOMETRIOSIS; EXOME; FEMALE; FUNCTIONAL PROTEOMICS; GENE MUTATION; GENOMICS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; OVARY CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEOGENOMIC ANALYSIS; REVERSE PHASE PROTEIN ARRAY; TUMOR GENE; UPREGULATION; ADENOCARCINOMA; CANCER GRADING; CLUSTER ANALYSIS; DNA MUTATIONAL ANALYSIS; GENE SILENCING; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MORTALITY; MUTATION; OUTCOME ASSESSMENT; PATHOLOGY; PHOSPHORYLATION; PROCEDURES; PROGNOSIS; PROTEOMICS; RNA INTERFERENCE;

ADENOCARCINOMA, CLEAR CELL; CARCINOMA, ENDOMETRIOID; CLUSTER ANALYSIS; DNA MUTATIONAL ANALYSIS; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; NEOPLASM GRADING; NEOPLASM STAGING; NUCLEAR PROTEINS; PATIENT OUTCOME ASSESSMENT; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROGNOSIS; PROTEOME; PROTEOMICS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RNA INTERFERENCE; TRANSCRIPTION FACTORS;

EID: 84895086287     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-120     Document Type: Article

References (38)

1. Kobel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM, Miller D, Santos J, Swenerton K, Gilks CB, Huntsman D. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008, 5(12):e232. 10.1371/journal.pmed.0050232, 2592352, 19053170.
2. Thigpen T, du Bois A, McAlpine J, DiSaia P, Fujiwara K, Hoskins W, Kristensen G, Mannel R, Markman M, Pfisterer J, Quinn M, Reed N, Swart AM, Berek J, Colombo N, Freyer G, Gallardo D, Plante M, Poveda A, Rubinstein L, Bacon M, Kitchener H, Stuart GC, Gynecologic Cancer InterGroup First-line therapy in ovarian cancer trials. Int J Gynecol Cancer 2011, 21(4):756-762. 10.1097/IGC.0b013e31821ce75d, 21543937, Gynecologic Cancer InterGroup.
3. Kobel M, Kalloger SE, Huntsman DG, Santos JL, Swenerton KD, Seidman JD, Gilks CB, Cheryl Brown Ovarian Cancer Outcomes Unit of the British Columbia Cancer Agency VBC Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol 2010, 29(3):203-211. 10.1097/PGP.0b013e3181c042b6, 20407318, Cheryl Brown Ovarian Cancer Outcomes Unit of the British Columbia Cancer Agency VBC.
4. Crum CP, Drapkin R, Miron A, Ince TA, Muto M, Kindelberger DW, Lee Y. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 2007, 19(1):3-9. 10.1097/GCO.0b013e328011a21f, 17218844.
5. Kuhn E, Kurman RJ, Vang R, Sehdev AS, Han G, Soslow R, Wang TL. Shih IeM: TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma-evidence supporting the clonal relationship of the two lesions. J Pathol 2012, 226(3):421-426. 10.1002/path.3023, 21990067.
6. LaGrenade A, Silverberg SG. Ovarian tumors associated with atypical endometriosis. Hum Pathol 1988, 19(9):1080-1084. 10.1016/S0046-8177(88)80090-X, 3417292.
7. Ogawa S, Kaku T, Amada S, Kobayashi H, Hirakawa T, Ariyoshi K, Kamura T, Nakano H. Ovarian endometriosis associated with ovarian carcinoma: a clinicopathological and immunohistochemical study. Gynecol Oncol 2000, 77(2):298-304. 10.1006/gyno.2000.5765, 10785482.
8. Vigano P, Somigliana E, Chiodo I, Abbiati A, Vercellini P. Molecular mechanisms and biological plausibility underlying the malignant transformation of endometriosis: a critical analysis. Hum Reprod Update 2006, 12(1):77-89.
9. Munksgaard PS, Blaakaer J. The association between endometriosis and gynecological cancers and breast cancer: a review of epidemiological data. Gynecol Oncol 2011, 123(1):157-163. 10.1016/j.ygyno.2011.06.017, 21742370.
10. Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM, Nagle CM, Doherty JA, Cushing-Haugen KL, Wicklund KG, Chang-Claude J, Hein R, Lurie G, Wilkens LR, Carney ME, Goodman MT, Moysich K, Kjaer SK, Hogdall E, Jensen A, Goode EL, Fridley BL, Larson MC, Schildkraut JM, Palmieri RT, Cramer DW, Terry KL, Vitonis AF, Titus LJ, Ziogas A, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 2012, 13(4):385-394. 10.1016/S1470-2045(11)70404-1, 3664011, 22361336.
11. Anglesio MS, Carey MS, Kobel M, Mackay H, Huntsman DG. Clear cell carcinoma of the ovary: a report from the first ovarian clear cell symposium, june 24th, 2010. Gynecol Oncol 2011, 121(2):407-415. 10.1016/j.ygyno.2011.01.005, 21276610.
12. Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, Yang W, Heravi-Moussavi A, Giuliany R, Chow C, Fee J, Zayed A, Prentice L, Melnyk N, Turashvili G, Delaney AD, Madore J, Yip S, McPherson AW, Ha G, Bell L, Fereday S, Tam A, Galletta L, Tonin PN, Provencher D, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010, 363(16):1532-1543. 10.1056/NEJMoa1008433, 2976679, 20942669.
13. Jones S, Wang TL, Shih I, Mao TL, Nakayama K, Roden R, Glas R, Slamon D, Diaz LA, Vogelstein B, Kinzler KW, Velculescu VE, Papadopoulos N. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Sci (New York, NY) 2010, 330(6001):228-231.
14. Guan B, Wang TL, Shih Ie M. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res 2011, 71(21):6718-6727. 10.1158/0008-5472.CAN-11-1562, 3206175, 21900401.
15. Lowery WJ, Schildkraut JM, Akushevich L, Bentley R, Marks JR, Huntsman D, Berchuck A. Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers. Int J Gynecol Cancer 2012, 22(1):9-14. 10.1097/IGC.0b013e318231f140, 3263359, 22193641.
16. Kuo KT, Mao TL, Jones S, Veras E, Ayhan A, Wang TL, Glas R, Slamon D, Velculescu VE, Kuman RJ, Shih I. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 2009, 174(5):1597-1601. 10.2353/ajpath.2009.081000, 2671248, 19349352.
17. Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, Cristiano BE, Pearson RB, Phillips WA. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004, 64(21):7678-7681. 10.1158/0008-5472.CAN-04-2933, 15520168.
18. Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K, Sahin A, Liu S, Barrera JA, Burgues O, Lluch AM, Chen H, Hortobagyi GN, Mills GB, Meric-Bernstam F. PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther 2011, 10(6):1093-1101. 10.1158/1535-7163.MCT-10-1089, 3112276, 21490305.
19. McConechy MK, Ding J, Cheang MC, Wiegand KC, Senz J, Tone AA, Yang W, Prentice LM, Tse K, Zeng T, McDonald H, Schmidt AP, Mutch DG, McAlpine JN, Hirst M, Shah SP, Lee CH, Goodfellow PJ, Gilks CB, Huntsman DG. Use of mutation profiles to refine the classification of endometrial carcinomas. J Pathol 2012, 228(1):20-30. 3939694, 22653804.
20. Liang H, Cheung LW, Li J, Ju Z, Yu S, Stemke-Hale K, Dogruluk T, Lu Y, Liu X, Gu C, Guo W, Scherer SE, Carter H, Westin SN, Dyer MD, Verhaak RG, Zhang F, Karchin R, Liu CG, Lu KH, Broaddus RR, Scott KL, Hennessy BT, Mills GB. Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res 2012, 22(11):2120-2129. 10.1101/gr.137596.112, 3483541, 23028188.
21. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005, 4(12):988-1004. 10.1038/nrd1902, 16341064.
22. Tibes R, Qiu Y, Lu Y, Hennessy B, Andreeff M, Mills GB, Kornblau SM. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther 2006, 5(10):2512-2521. 10.1158/1535-7163.MCT-06-0334, 17041095.
23. Anderson CL, Wang Y, Rustandi RR. Applications of imaged capillary isoelectric focussing technique in development of biopharmaceutical glycoprotein-based products. Electrophoresis 2012, 33(11):1538-1544. 10.1002/elps.201100611, 22736354.
24. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008, 68(15):6084-6091. 10.1158/0008-5472.CAN-07-6854, 2680495, 18676830.
25. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001, 98(9):5116-5121. 10.1073/pnas.091062498, 33173, 11309499.
26. Ho CM, Lin MC, Huang SH, Huang CJ, Lai HC, Chien TY, Chang SF. PTEN promoter methylation and LOH of 10q22-23 locus in PTEN expression of ovarian clear cell adenocarcinomas. Gynecol Oncol 2009, 112(2):307-313. 10.1016/j.ygyno.2008.09.040, 19007975.
27. Iacovides DC, Johnson AB, Wang N, Boddapatti S, Korkola J, Gray JW. Identification and quantification of AKT isoforms and phosphoforms in breast cancer using a novel nanofluidic immunoassay. Mol Cell Proteomics 2013, 12(11):3210-3220. 10.1074/mcp.M112.023119, 23929892.
28. Kamel D, Brady B, Tabchy A, Mills GB, Hennessy B. Proteomic classification of breast cancer. Curr Drug Targets 2012, 13(12):1495-1509. 10.2174/138945012803530080, 22974393.
29. Yang JY, Yoshihara K, Tanaka K, Hatae M, Masuzaki H, Itamochi H, Takano M, Ushijima K, Tanyi JL, Coukos G, Lu Y, Mills GB, Verhaak RG. Predicting time to ovarian carcinoma recurrence using protein markers. J Clin Invest 2013, 123(9):3740-3750. 3754259, 23945238.
30. Carey MS, Agarwal R, Gilks B, Swenerton K, Kalloger S, Santos J, Ju Z, Lu Y, Zhang F, Coombes KR, Miller D, Huntsman D, Mills GB, Hennessy BT. Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy. Clin Cancer Res 2010, 16(10):2852-2860. 10.1158/1078-0432.CCR-09-2502, 2877659, 20460476.
31. Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov 2011, 1(2):170-185. 10.1158/2159-8290.CD-11-0039, 3187555, 21984976.
32. Cizkova M, Susini A, Vacher S, Cizeron-Clairac G, Andrieu C, Driouch K, Fourme E, Lidereau R, Bieche I. PIK3CA mutation impact on survival in breast cancer patients and in ERalpha, PR and ERBB2-based subgroups. Breast Cancer Res 2012, 14(1):R28. 10.1186/bcr3113, 3496146, 22330809.
33. Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, Kim JJ, Hennessy BT, Tseng H, Pochanard P, Kim SY, Dunn IF, Schinzel AC, Sandy P, Hoersch S, Sheng Q, Gupta PB, Boehm JS, Reiling JH, Silver S, Lu Y, Stemke-Hale K, Dutta B, Joy C, Sahin AA, Gonzalez-Angulo AM, Lluch A, Rameh LE, Jacks T, Root DE, Lander ES, Lluch A, et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 2009, 16(1):21-32. 10.1016/j.ccr.2009.04.012, 2752826, 19573809.
34. Fadare O, Gwin K, Desouki MM, Crispens MA, Jones HW, Khabele D, Liang SX, Zheng W, Mohammed K, Hecht JL, Parkash V. The clinicopathologic significance of BAF250a (AIRD1A) expression in clear cell carcinomas of the endometrium. Mol Pathol 2013, 26(8):1101-1110.
35. Balbas-Martinez C, Rodriguez-Pinilla M, Casanova A, Dominguez O, Pisano DG, Gomez G, Lloreta J, Lorente JA, Malats N, Real FX. ARID1A alterations are associated with FGFR3-wild type, poor prognosis, urothelial bladder tumors. PLoS One 2013, 8(5):e62483. 10.1371/journal.pone.0062483, 3641081, 23650517.
36. Agarwal R, Carey M, Hennessy B, Mills GB. PI3K pathway-directed therapeutic strategies in cancer. Curr Opin Investig Drugs 2010, 11:615-628.
37. Mackay HJ, Brady MF, Oza AM, Reuss A, Pujade-Lauraine E, Swart AM, Siddiqui N, Colombo N, Bookman MA, Pfisterer J, du Bois A, Gynecologic Cancer InterGroup Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer 2010, 20(6):945-952. 10.1111/IGC.0b013e3181dd0110, 20683400, Gynecologic Cancer InterGroup.
38. Takakura S, Takano M, Takahashi F, Saito T, Aoki D, Inaba N, Noda K, Sugiyama T, Ochiai K, Japanese Gynecologic Oncology G Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study. Int J Gynecol Cancer 2010, 20(2):240-247. 10.1111/IGC.0b013e3181cafb47, 20169667, Japanese Gynecologic Oncology G.